title: Piperine inhibits type II phosphatidylinositol 4-kinases: a key component in phosphoinositides turnover.
abstract: Piperine has been shown to have anti-inflammatory properties. The molecular mechanisms by which it mediates anti-inflammatory activities remain elusive. Type II phosphatidylinositol 4-kinase(s) are key components in FcεRI receptor-mediated signaling leading to inflammatory mediators release in RBL-2H3 cells. The effects of piperine on IgE-mediated signaling and mast cell degranulation were investigated. Pretreatment of RBL-2H3 cells with piperine inhibited IgE-induced activation of type II PtdIns 4-kinase(s). In vitro lipid kinase assays showed piperine-inhibited type II PtdIns 4-kinase activity in a dose-dependent fashion with no effect on PtdIns 3-kinase activity. Concomitantly, pretreatment of RBL-2H3 cells with piperine also inhibited IgE-induced β-hexosaminidase release in RBL-2H3 cells. These results suggest that type II PtdIns 4-kinases are part of piperine-mediated anti-inflammatory signaling mechanisms.
authors.affiliation: Department of Biosciences and Bioengineering, Wadhwani Research Centre, Indian Institute of Technology Bombay, Powai, Mumbai, 400076, India, naveenb@u.washington.edu.
authors.forename: Naveen
authors.initials: N
authors.lastname: Bojjireddy
authors.forename: Ranjeet Kumar
authors.initials: RK
authors.lastname: Sinha
authors.forename: Gosukonda
authors.initials: G
authors.lastname: Subrahmanyam
mesh_terms: D000470:Alkaloids / Q000008:administration & dosage*; D052117:Benzodioxoles / Q000008:administration & dosage*; D002460:Cell Line; D006801:Humans; D007073:Immunoglobulin E / Q000276:immunology / Q000378:metabolism; D007249:Inflammation / Q000188:drug therapy / Q000235:genetics* / Q000473:pathology; D008407:Mast Cells / Q000276:immunology / Q000473:pathology; D015778:Minor Histocompatibility Antigens; D010716:Phosphatidylinositols / Q000378:metabolism*; D010766:Phosphorylation / Q000187:drug effects; D017853:Phosphotransferases (Alcohol Group Acceptor) / Q000037:antagonists & inhibitors / Q000378:metabolism*; D010880:Piperidines / Q000008:administration & dosage*; D053284:Polyunsaturated Alkamides / Q000008:administration & dosage*; D017455:Receptors, IgE / Q000276:immunology / Q000378:metabolism; D015398:Signal Transduction / Q000187:drug effects
chemical_list: D000470:Alkaloids; D052117:Benzodioxoles; D015778:Minor Histocompatibility Antigens; D010716:Phosphatidylinositols; D010880:Piperidines; D053284:Polyunsaturated Alkamides; D017455:Receptors, IgE; D007073:Immunoglobulin E; D017853:Phosphotransferases (Alcohol Group Acceptor); C402182:phosphatidylinositol phosphate 4-kinase; C008922:piperine